Niagen Bioscience, Inc. (NAGE) Cash and Cash Equivalents

Annual Cash & Cash Equivalents:

$44.66M+$17.34M(+63.44%)
December 31, 2024

Summary

  • As of today, NAGE annual cash & cash equivalents is $44.66 million, with the most recent change of +$17.34 million (+63.44%) on December 31, 2024.
  • During the last 3 years, NAGE annual cash & cash equivalents has risen by +$16.44 million (+58.26%).
  • NAGE annual cash & cash equivalents is now -1.61% below its all-time high of $45.39 million, reached on December 1, 2017.

Performance

1-Year Change

+63.44%

3-Year Change

+58.26%

5-Year Change

+137.4%

15-Year Change

-1.61%

NAGE Cash and Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

50.42%
NAGE annual cash & cash equivalents is higher than 50.42% of companies in Healthcare sector

Range

All-Time High

$45.39M
NAGE annual cash & cash equivalents is currently -1.61% below its historical high of $45.39 million

3-Year Low

$20.44M
NAGE annual cash & cash equivalents is currently +118.48% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
NAGE previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

Mar 4, 2026
NAGE next annual earnings announcement is scheduled for Mar 4, 2026

OtherNAGEbalance sheet metrics

Quarterly Total Assets

$98.14M
NAGE quarterly total assets is $98.14 million

Quarterly Current Assets

$93.62M
NAGE quarterly total current assets is $93.62 million

Quarterly Total Liabilities

$27.46M
NAGE quarterly total liabilities is $27.46 million

Quarterly Current Liabilities

$22.71M
NAGE quarterly current liabilities is $22.71 million

Quarterly Cash & Cash Equivalents:

$64.29M+$3.82M(+6.31%)
September 30, 2025

Summary

  • As of today, NAGE quarterly cash & cash equivalents is $64.29 million, with the most recent change of +$3.82 million (+6.31%) on September 30, 2025.
  • Over the past year, NAGE quarterly cash & cash equivalents has increased by +$31.89 million (+98.44%).
  • NAGE quarterly cash & cash equivalents is now at all-time high.

Performance

3-Month Change

+6.31%

1-Year Change

+98.44%

3-Year Change

+384.77%

5-Year Change

+315.36%

NAGE Quarterly Cash & Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

50.3%
NAGE quarterly cash & cash equivalents is higher than 50.3% of companies in Healthcare sector

Range

All-Time High

$64.29M
NAGE quarterly cash & cash equivalents is currently at an all-time high

3-Year Low

$13.26M
NAGE quarterly cash & cash equivalents is currently +384.77% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2025
NAGE previous earnings announcement was published on Sep 30, 2025

Next Quarterly Earnings Report Date

Mar 4, 2026
NAGE next earnings announcement is scheduled for Mar 4, 2026

OtherNAGEbalance sheet metrics

Quarterly Total Assets

$98.14M
NAGE quarterly total assets is $98.14 million

Quarterly Current Assets

$93.62M
NAGE quarterly total current assets is $93.62 million

Quarterly Total Liabilities

$27.46M
NAGE quarterly total liabilities is $27.46 million

Quarterly Current Liabilities

$22.71M
NAGE quarterly current liabilities is $22.71 million

Cash and Cash Equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

NAGE Cash and Cash Equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1Y1 Year+63.4%+98.4%
3Y3 Years+58.3%+384.8%
5Y5 Years+137.4%+315.4%

NAGE Cash and Cash Equivalents Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs Low
3Y3-Yearat high+118.5%at high+384.8%
5Y5-Yearat high+167.5%at high+384.8%
All-TimeAll-Time-1.6%>+9999.0%at high>+9999.0%

NAGE Cash and Cash Equivalents History

DateAnnualQuarterly
Sep 2025
-
$64.29M(+6.3%)
Jun 2025
-
$60.47M(+8.7%)
Mar 2025
-
$55.62M(+24.5%)
Dec 2024
$44.66M(+63.4%)
$44.66M(+37.8%)
Sep 2024
-
$32.40M(+16.2%)
Jun 2024
-
$27.89M(+1.2%)
Mar 2024
-
$27.57M(+0.9%)
Dec 2023
$27.32M(+33.7%)
-
Dec 2023
-
$27.32M(+2.1%)
Sep 2023
-
$26.77M(+1.4%)
Jun 2023
-
$26.41M(+14.1%)
Mar 2023
-
$23.14M(+13.2%)
Dec 2022
$20.44M(-27.6%)
$20.44M(+54.1%)
Sep 2022
-
$13.26M(-22.3%)
Jun 2022
-
$17.07M(-18.7%)
Mar 2022
-
$20.99M(-25.6%)
Dec 2021
$28.22M(+69.0%)
$28.22M(-14.8%)
Sep 2021
-
$33.10M(-14.6%)
Jun 2021
-
$38.78M(-13.2%)
Mar 2021
-
$44.69M(+167.7%)
Dec 2020
$16.70M(-11.2%)
$16.70M(+7.9%)
Sep 2020
-
$15.48M(-18.1%)
Jun 2020
-
$18.89M(+38.8%)
Mar 2020
-
$13.61M(-27.7%)
Dec 2019
$18.81M(-16.8%)
$18.81M(-0.4%)
Sep 2019
-
$18.88M(-4.5%)
Jun 2019
-
$19.76M(+2.2%)
Mar 2019
-
$19.33M(-14.5%)
Dec 2018
$22.62M(-50.2%)
$22.62M(-19.8%)
Sep 2018
-
$28.21M(-15.5%)
Jun 2018
-
$33.39M(-18.6%)
Mar 2018
-
$41.04M(-9.6%)
Dec 2017
$45.39M(+2663.6%)
$45.39M(+89.1%)
Sep 2017
-
$24.00M(+69.7%)
Jun 2017
-
$14.14M(+1092.7%)
Mar 2017
-
$1.19M(-27.8%)
Dec 2016
$1.64M
$1.64M(-27.5%)
DateAnnualQuarterly
Sep 2016
-
$2.26M(-32.8%)
Jun 2016
-
$3.37M(+12.5%)
Mar 2016
-
$3.00M(-46.0%)
Dec 2015
$5.55M(+40.0%)
$5.55M(+17.9%)
Sep 2015
-
$4.71M(-17.4%)
Jun 2015
-
$5.70M(+77.2%)
Mar 2015
-
$3.22M(-18.9%)
Dec 2014
$3.96M(+75.3%)
$3.96M(+229.4%)
Sep 2014
-
$1.20M(-6.0%)
Jun 2014
-
$1.28M(-33.5%)
Mar 2014
-
$1.92M(-14.9%)
Dec 2013
$2.26M(+334.9%)
$2.26M(+108.0%)
Sep 2013
-
$1.09M(+31.6%)
Jun 2013
-
$826.60K(-14.5%)
Mar 2013
-
$966.60K(+85.9%)
Dec 2012
$520.00K(+23.8%)
$520.00K(-58.0%)
Sep 2012
-
$1.24M(-44.1%)
Jun 2012
-
$2.21M(-61.9%)
Mar 2012
-
$5.81M(+1281.5%)
Dec 2011
$420.20K(-81.1%)
$420.20K(-79.7%)
Sep 2011
-
$2.07M(+1.2%)
Jun 2011
-
$2.04M(-29.4%)
Mar 2011
-
$2.90M(+30.1%)
Dec 2010
$2.23M(+372.3%)
$2.23M(-25.4%)
Sep 2010
-
$2.99M(-11.7%)
Jun 2010
-
$3.38M(+527.8%)
Mar 2010
-
$538.70K(+14.3%)
Dec 2009
$471.40K(-58.1%)
$471.40K(-6.0%)
Sep 2009
-
$501.40K(-17.3%)
Jun 2009
-
$606.60K(-28.0%)
Mar 2009
-
$843.00K(-25.1%)
Dec 2008
$1.13M(>+9900.0%)
$1.13M(-53.5%)
Sep 2008
-
$2.42M(+0.2%)
Jun 2008
-
$2.42M(>+9900.0%)
Nov 2007
$600.00
$600.00(-85.7%)
Aug 2007
-
$4200.00(-50.6%)
May 2007
-
$8500.00(-19.8%)
Feb 2007
-
$10.60K

FAQ

  • What is Niagen Bioscience, Inc. annual cash & cash equivalents?
  • What is the all-time high annual cash & cash equivalents for Niagen Bioscience, Inc.?
  • What is Niagen Bioscience, Inc. annual cash & cash equivalents year-on-year change?
  • What is Niagen Bioscience, Inc. quarterly cash & cash equivalents?
  • What is the all-time high quarterly cash & cash equivalents for Niagen Bioscience, Inc.?
  • What is Niagen Bioscience, Inc. quarterly cash & cash equivalents year-on-year change?

What is Niagen Bioscience, Inc. annual cash & cash equivalents?

The current annual cash & cash equivalents of NAGE is $44.66M

What is the all-time high annual cash & cash equivalents for Niagen Bioscience, Inc.?

Niagen Bioscience, Inc. all-time high annual cash & cash equivalents is $45.39M

What is Niagen Bioscience, Inc. annual cash & cash equivalents year-on-year change?

Over the past year, NAGE annual cash & cash equivalents has changed by +$17.34M (+63.44%)

What is Niagen Bioscience, Inc. quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of NAGE is $64.29M

What is the all-time high quarterly cash & cash equivalents for Niagen Bioscience, Inc.?

Niagen Bioscience, Inc. all-time high quarterly cash & cash equivalents is $64.29M

What is Niagen Bioscience, Inc. quarterly cash & cash equivalents year-on-year change?

Over the past year, NAGE quarterly cash & cash equivalents has changed by +$31.89M (+98.44%)
On this page